AstraZeneca's Enhertu Breast Cancer Drug Gets UK Recommendation

03:35 AM EDT, 09/17/2026 (MT Newswires) -- AstraZeneca's (AZN) breast cancer drug Enhertu, developed with Daiichi Sankyo, received a recommendation from UK's National Institute for Health and Care Excellence for routine use through the National Health Service, the agency said Thursday. The recommendation covers around 1000 people with HER2-low advanced breast cancer whose disease has progressed following treatment, NICE said. The agency said a commercial agreement on the use of Enhertu was reached following changes to its cost effectiveness thresholds and a new method for assessing quality of life.